Hardly any of them expect a major decline.
The EBITDA and EPS estimates have also been upped.
To HUF 570 per share from HUF 600.
J.P. Morgan also cuts rating.
U.S. FDA rejects application by Allergan.
Profit was up by a third.
Q2 earnings report to be released on Wednesday.
Equilor makes it to the Top3.
OTP enters a new market, becomes market leader in another.
Richter pampers shareholders with positive surprises.
The seller is SocGen.
There are some crucial questions, though.
Mol is also set to release earnings report this week.
European Commission takes decision.
Earnings report to be released next week.
Q2 profit could be larger than previous annual profits.
The new TP still offers major upside potential, though.
OTP comments Q2 earnings report.
Over 3.77 million shares.